Neural Therapeutics Strengthens IP Portfolio With a Patent Application
Treatment of Major DSM-5 Disorders, Including Addiction, Depression and Anxiety, With Sub-Hallucinogenic Mescaline DosesExtraction Technology Delivering Higher Yields and Greater PurityFrankfurt Stock Exchange Ticker Symbol Changed to "HANF"Extension of LOI with CWE European Holdings (dba Hanf.com) Toronto, Ontario--(Newsfile Corp. - April 14, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company dedicated to developing the